Akeylink Biotechnology

Akeylink Biotechnology is a biopharmaceutical company specializing in the development of next-generation targeted protein degradation (TPD) therapies. Founded by Dr. Haizhou Zhang, a former senior scientist at Arvinas, the company leverages its proprietary AkeyLink platform to design and optimize bifunctional molecules such as PROTACs. The AkeyLink technology utilizes a modular assembly approach to overcome traditional challenges in linker design and E3 ligase selection, aiming to target proteins previously considered "undruggable." Based in Hangzhou, China, Akeylink is advancing a pipeline of pre-clinical programs focused on oncology and autoimmune diseases. The company has successfully raised significant capital from leading investors like Qiming Venture Partners and Legend Capital to support its drug discovery efforts.